These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12837733)

  • 1. Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats.
    Marier JF; Brazier JL; Lavigne J; Ducharme MP
    J Antimicrob Chemother; 2003 Aug; 52(2):247-52. PubMed ID: 12837733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aerosolization of low phase transition temperature liposomal tobramycin as a dry powder in an animal model of chronic pulmonary infection caused by Pseudomonas aeruginosa.
    Beaulac C; Sachetelli S; Lagacé J
    J Drug Target; 1999; 7(1):33-41. PubMed ID: 10614813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and efficacies of liposomal and conventional formulations of tobramycin after intratracheal administration in rats with pulmonary Burkholderia cepacia infection.
    Marier JF; Lavigne J; Ducharme MP
    Antimicrob Agents Chemother; 2002 Dec; 46(12):3776-81. PubMed ID: 12435676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection.
    Alhariri M; Omri A
    Antimicrob Agents Chemother; 2013 Jan; 57(1):569-78. PubMed ID: 23147741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bismuth-thiol incorporation enhances biological activities of liposomal tobramycin against bacterial biofilm and quorum sensing molecules production by Pseudomonas aeruginosa.
    Halwani M; Hebert S; Suntres ZE; Lafrenie RM; Azghani AO; Omri A
    Int J Pharm; 2009 May; 373(1-2):141-6. PubMed ID: 19429299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model.
    Morinaga Y; Yanagihara K; Nakamura S; Yamamoto K; Izumikawa K; Seki M; Kakeya H; Yamamoto Y; Yamada Y; Kohno S; Kamihira S
    J Antimicrob Chemother; 2008 Dec; 62(6):1326-31. PubMed ID: 18835805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection.
    Beaulac C; Clément-Major S; Hawari J; Lagacé J
    Antimicrob Agents Chemother; 1996 Mar; 40(3):665-9. PubMed ID: 8851590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal bismuth-ethanedithiol formulation enhances antimicrobial activity of tobramycin.
    Halwani M; Blomme S; Suntres ZE; Alipour M; Azghani AO; Kumar A; Omri A
    Int J Pharm; 2008 Jun; 358(1-2):278-84. PubMed ID: 18448284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuation of Pseudomonas aeruginosa virulence factors and biofilms by co-encapsulation of bismuth-ethanedithiol with tobramycin in liposomes.
    Alipour M; Suntres ZE; Lafrenie RM; Omri A
    J Antimicrob Chemother; 2010 Apr; 65(4):684-93. PubMed ID: 20159770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections.
    Meers P; Neville M; Malinin V; Scotto AW; Sardaryan G; Kurumunda R; Mackinson C; James G; Fisher S; Perkins WR
    J Antimicrob Chemother; 2008 Apr; 61(4):859-68. PubMed ID: 18305202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vivo impact of the MexXY efflux system on aminoglycoside efficacy in an experimental model of Pseudomonas aeruginosa pneumonia treated with tobramycin.
    Martha B; Croisier D; Durand D; Hocquet D; Plesiat P; Piroth L; Portier H; Chavanet P
    Clin Microbiol Infect; 2006 May; 12(5):426-32. PubMed ID: 16643518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposome encapsulation: a method for enhancing the effectiveness of local antibiotics.
    Price CI; Horton JW; Baxter CR
    Surgery; 1994 Apr; 115(4):480-7. PubMed ID: 8165539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
    Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
    J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa.
    Omri A; Beaulac C; Bouhajib M; Montplaisir S; Sharkawi M; Lagacé J
    Antimicrob Agents Chemother; 1994 May; 38(5):1090-5. PubMed ID: 8067743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-administration of aqueous ginseng extract with tobramycin stimulates the pro-inflammatory response and promotes the killing of Pseudomonas aeruginosa in the lungs of infected rats.
    Alipour M; Omri A; Lui EM; Suntres ZE
    Can J Physiol Pharmacol; 2013 Nov; 91(11):935-40. PubMed ID: 24117261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of a new tobramycin (0.3%) and dexamethasone (0.05%) formulation in the treatment of experimental Pseudomonas keratitis.
    McCormick C; Caballero A; Tang A; Balzli C; Song J; O'Callaghan R
    Curr Med Res Opin; 2008 Jun; 24(6):1569-75. PubMed ID: 18423106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo efficacy of humanised intermittent versus continuous ceftazidime in combination with tobramycin in an experimental model of pseudomonal pneumonia.
    Croisier D; Martha B; Piroth L; Chavanet P
    Int J Antimicrob Agents; 2008 Dec; 32(6):494-8. PubMed ID: 18804348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and tissue distribution of d-alpha-tocopheryl succinate formulations following intravenous administration in the rat.
    Teng XW; Davies NM; Fukuda C; Good RL; Fariss MW
    Biopharm Drug Dispos; 2005 Jul; 26(5):195-203. PubMed ID: 15900617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
    Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
    Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa.
    Maciá MD; Borrell N; Segura M; Gómez C; Pérez JL; Oliver A
    Antimicrob Agents Chemother; 2006 Mar; 50(3):975-83. PubMed ID: 16495260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.